Press releases
- Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
- Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
- Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
More ▼
Key statistics
As of last trade, Relmada Therapeutics Inc (4E2:MUN) traded at 3.80, 82.69% above the 52 week low of 2.08 set on Dec 09, 2022.
52-week range
Markit short selling activity
Open | 3.80 |
---|---|
High | 3.80 |
Low | 3.80 |
Bid | 3.76 |
Offer | 3.86 |
Previous close | 3.84 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.10m |
Free float | 29.71m |
P/E (TTM) | -- |
Market cap | 122.20m USD |
EPS (TTM) | -5.85 USD |
Data delayed at least 15 minutes, as of Jan 31 2023 07:01 GMT.
More ▼